Novo Nordisk Crecimiento futuro

Future controles de criterios 4/6

Novo Nordisk se prevé un crecimiento anual de los beneficios y los ingresos de 13.8% y 13.6% respectivamente. Se prevé que el BPA sea de grow en 15.1% al año. Se prevé que la rentabilidad de los fondos propios sea de 72.8% en 3 años.

Información clave

14.8%

Tasa de crecimiento de los beneficios

14.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	21.0%
Tasa de crecimiento de los ingresos	13.9%
Rentabilidad financiera futura	84.7%
Cobertura de analistas	Good
Última actualización	19 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OTCPK:NONO.F - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	398,847	146,902	120,286	165,178	21
12/31/2025	345,526	125,189	99,159	143,316	25
12/31/2024	287,398	103,654	64,793	124,529	25
12/31/2023	232,261	83,683	70,012	108,908	N/A
9/30/2023	214,490	75,312	77,825	106,458	N/A
6/30/2023	201,325	67,239	67,497	89,731	N/A
3/31/2023	188,290	61,129	67,341	85,115	N/A
12/31/2022	176,954	55,525	64,134	78,887	N/A
9/30/2022	167,195	52,825	57,875	68,769	N/A
6/30/2022	157,251	50,539	57,680	66,037	N/A
3/31/2022	149,027	49,344	59,665	67,331	N/A
12/31/2021	140,800	47,757	47,615	55,000	N/A
9/30/2021	134,605	46,183	40,213	58,189	N/A
6/30/2021	129,910	44,362	31,814	54,188	N/A
3/31/2021	126,875	42,864	31,337	53,194	N/A
12/31/2020	126,946	42,138	29,870	51,951	N/A
9/30/2020	127,225	41,537	44,800	56,944	N/A
6/30/2020	126,575	41,433	47,621	56,126	N/A
3/31/2020	126,605	40,403	36,987	46,904	N/A
12/31/2019	122,021	38,951	35,551	46,782	N/A
9/30/2019	119,336	38,731	36,785	49,029	N/A
6/30/2019	116,821	37,574	31,251	43,960	N/A
3/31/2019	114,192	38,322	32,202	44,691	N/A
12/31/2018	111,831	38,628	32,206	44,616	N/A
9/30/2018	110,091	38,384	31,576	43,236	N/A
6/30/2018	108,943	39,117	33,787	44,538	N/A
3/31/2018	110,174	38,725	28,991	38,885	N/A
12/31/2017	111,696	38,130	32,520	41,168	N/A
9/30/2017	113,276	38,576	N/A	46,289	N/A
6/30/2017	114,199	38,609	N/A	48,557	N/A
3/31/2017	113,020	38,626	N/A	52,937	N/A
12/31/2016	111,780	37,925	N/A	48,314	N/A
9/30/2016	111,084	37,484	N/A	47,280	N/A
6/30/2016	110,339	36,064	N/A	44,179	N/A
3/31/2016	109,939	34,439	N/A	41,656	N/A
12/31/2015	107,927	34,860	N/A	38,287	N/A
9/30/2015	103,636	33,131	N/A	35,469	N/A
6/30/2015	99,093	31,248	N/A	35,578	N/A
3/31/2015	93,663	29,899	N/A	31,729	N/A
12/31/2014	88,806	26,481	N/A	31,692	N/A
9/30/2014	85,919	26,005	N/A	29,763	N/A
6/30/2014	84,181	25,920	N/A	23,783	N/A
3/31/2014	83,932	25,660	N/A	22,941	N/A
12/31/2013	83,572	25,184	N/A	25,942	N/A
9/30/2013	82,836	24,886	N/A	22,084	N/A
6/30/2013	82,170	24,138	N/A	23,829	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: NONO.F(15.2% al año) es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: NONO.FSe prevé que los beneficios de la empresa (14.8% al año) crezcan más deprisa que el mercado US (14.6% al año).

Beneficios de alto crecimiento: NONO.FSe prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: NONO.FSe prevé que los ingresos de la empresa (14.6% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: NONO.FSe prevé que los ingresos de la empresa (14.6% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: NONO.FSe prevé que la Rentabilidad de los fondos propios de la empresa sea muy elevada dentro de 3 años (72.8%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Novo Nordisk Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S Revises Earnings Guidance for the Full Year of 2022

Novo Nordisk A/S Provides Earnings Guidance for the Year 2022

Recent updates

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 28,000 million worth of its shares.

Novo Nordisk Announces FDA Approval of Label Update for Rybelsus® (Semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes

Novo Nordisk A/S to Report First Half, 2023 Results on Aug 10, 2023

Novo Nordisk Announces Headline Results from the ONWARDS 5 Phase 3A Trial with Once-Weekly Insulin Icodec in People with Type 2 Diabetes

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. (NasdaqGM:FMTX) from RA Capital Management, L.P. and others for approximately $990 million

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. (NasdaqGM:FMTX) from RA Capital Management, L.P. and others for approximately $990 million

Novo Nordisk A/S Successfully Completes Phase 2 Trial with Cagrisema in People with Type 2 Diabetes

Novo Nordisk A/S Revises Earnings Guidance for the Full Year of 2022

Novo Nordisk Achieves Primary Objectives of Onwards 3 and 4 Trials with Once-Weekly Insulin Icodec Demonstrating Superior Reduction in Hba1c Vs Insulin Degludec in Onwards 3

Novo Nordisk Achieves Primary Objectives of ONWARDS 1 and 6 Trials

Novo Nordisk A/S to Report Fiscal Year 2022 Results on Feb 01, 2023

Novo Nordisk Announces US Food and Drug Administration Approve A 2.0 Mg Dose of Ozempic®

Novo Nordisk A/S Announces Board Changes

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 22,000 million worth of its shares.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2022

Novo Nordisk A/S Announces Settlement of Securities Lawsuit in Denmark

Novo Nordisk Announces Health Canada Approves Wegovy™ for the Treatment of Adults with Obesity

Novo Nordisk Presents Investigational 2 Mg Dose of Ozempic® (Semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar Vs Ozempic® 1 Mg in Adults with Type 2 Diabetes in A Phase 3 Trial

US Food and Drug Administration Approves Wegovy of Novo Nordisk

Novo Nordisk Resubmits Once-Weekly Semaglutide 2.0 Mg for the Treatment of Type 2 Diabetes for US Regulatory Approval

Novo Nordisk Presents Results from RESCUE

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento